Morgan Stanley raised the firm’s price target on Abbott (ABT) to $137 from $127 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- ABT Earnings this Week: How Will it Perform?
- Abbott price target raised to $148 from $145 at BTIG
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025
- Abbott Laboratories Positioned for Growth: Buy Rating Supported by Strong Operational Momentum and Favorable Market Conditions
- Abbott price target raised to $157 from $155 at Citi